Beckman Coulter's Q2 Revenues Increase 19 Percent; Misses Estimates

The firm's revenues were aided by a $116.6 million contribution from Olympus Diagnostics, which the firm bought last year. It missed analysts' estimates and offered a disappointing forecast, sending its shares down sharply.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories